GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vectus Biosystems Ltd (ASX:VBS) » Definitions » Other Operating Expense

Vectus Biosystems (ASX:VBS) Other Operating Expense : A$-0.01 Mil (TTM As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Vectus Biosystems Other Operating Expense?

Vectus Biosystems's Other Operating Expense for the six months ended in Dec. 2024 was A$0.13 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 was A$-0.01 Mil.

Vectus Biosystems's quarterly Other Operating Expense declined from Dec. 2023 (A$0.20 Mil) to Jun. 2024 (A$-0.14 Mil) but then increased from Jun. 2024 (A$-0.14 Mil) to Dec. 2024 (A$0.13 Mil).

Vectus Biosystems's annual Other Operating Expense increased from Jun. 2022 (A$0.02 Mil) to Jun. 2023 (A$0.07 Mil) but then declined from Jun. 2023 (A$0.07 Mil) to Jun. 2024 (A$0.06 Mil).


Vectus Biosystems Other Operating Expense Historical Data

The historical data trend for Vectus Biosystems's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vectus Biosystems Other Operating Expense Chart

Vectus Biosystems Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only 0.04 0.02 0.02 0.07 0.06

Vectus Biosystems Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.52 -0.45 0.20 -0.14 0.13

Vectus Biosystems Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vectus Biosystems Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Vectus Biosystems's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Vectus Biosystems Business Description

Traded in Other Exchanges
N/A
Address
26-34 Dunning Avenue, Unit 5, Ground Floor, Rosebery, Sydney, NSW, AUS, 2018
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company has developed and patented various novel compounds for the treatment of chronic fibrosis, including heart, kidney, liver, and lung fibrosis. Its drug candidate VB0004, is aimed at inhibiting and reversing the loss of functional tissue due to fibrosis, is in its human trials phase. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. It operates in one segment, being pharmaceutical research and development.

Vectus Biosystems Headlines

No Headlines